Amgen-Horizon Deal Challenge Paused by FTC for Settlement Talks
The Federal Trade Commission said it would pause its in-house proceedings to block Amgen Inc.’s $27.8 billion takeover of Horizon Therapeutics Plc, opening the door to settlement talks that could resolve the agency’s challenge to the deal.